risk of developing metabolic aberrations, such as type 2 diabetes (T2D), non-alcoholic fatty liver disease and cardiovascular disease, all of which start in adolescence. 1, 3, 4 The Joint 2017 Pediatric Endocrine
Society and North American Society for Adolescent and Pediatric
Gynecology Guidelines for PCOS diagnosis and management in adolescents recommend that the presence of IR prompt further comorbidity testing and treatment with metformin. 5 The 2013 Endocrine Society guidelines suggest the use of metformin as a second-line therapy in PCOS youth with hyperglycemia, defined as impaired glucose tolerance (IGT) or T2D. 1 It recommends the use of 2-hour oral glucose tolerance test (OGTT) with a 2-hour glucose measurement to screen for IGT, defined as a blood glucose ≥140 mg/dL. Both guidelines were developed out of recognition that PCOS in adolescents may not be the same as in adult women, in part because of more severe IR secondary to pubertal changes. 1, 6 Yet, despite recognition of unique metabolism of IR in adolescents and screening recommendations, IR is best measured by a hyperinsulinemic-euglycemic clamp and IGT by an OGTT, both of which are burdensome for clinical care.
A simple surrogate measure of IR for youth with PCOS is needed.
Many surrogate measures of IR have been developed in non-
PCOS populations, validated against the glucose infusion rate (GIR) during a hyperinsulinemic-euglycemic clamp, which is considered the gold standard for measuring insulin sensitivity, but impractical for clinical care. 7 Homeostatic model assessment-insulin resistant (HOMA-IR) is the most used index and has been shown to be a reliable indicator of IR in large-scale studies, given its tight correlation (r = 0.88) with the clamp. 2, 8 Nonetheless, HOMA-IR has a 30% intra-individual variation limiting its use in individuals for clinical care. Other insulinbased surrogates of IR include a fasting insulin, the fasting glucose to insulin ratio (FGIR), 9 the quantitative insulin sensitivity check (QUICKI) 10 and OGTT models, such as the Matsuda 11 or Stumvoll. 12 However, all of these models include fasting insulin, which can vary from day-to-day and insulin assays are still largely unstandardized. 13, 14 These measures have all been shown to have various degrees of success in predicting IR in adults with PCOS, but have not been studied as predictors of IR in youth with PCOS. [15] [16] [17] Serum triglycerides (TG) and high-density lipoprotein cholesterol (HDL) are also associated with IR, have less inter-assay and day-to-day variability, and do not add additional cost as they are already recommended for screening of lipid abnormalities in PCOS. 18 In a PCOS adult cohort, TG alone was identified as an effective marker in identifying IR, tightly correlating to HOMA-IR. 19 Song et al. also suggested TG:HDL to be a strong indicator of IR in young women with PCOS, when compared to OGTT models. 20 A TG and glucose index (TyG) also correlated well with GIR, and was found to work well in a pediatric obese population of youth. 18, 21 We previously developed and validated a surrogate estimate of insulin sensitivity (e-IS) against GIR, in adolescents of varied BMI and with and without diabetes. 22 The e-IS calculation also uses TG, as well as HbA1c and waist circumference and does not use insulin. 22 Thus, there are numerous surrogate markers of IR, which have been used in obese youth, however, the most applicable for adolescents with PCOS is not clear.
Many surrogate measures for IGT have also been tested, in an effort to avoid performing an OGTT. The most commonly identified markers are HOMA-IR and fasting insulin, although multiple other markers including HbA1c and adiponectin have been proposed. [23] [24] [25] [26] However, many studies failed to find strong predictors for IGT in either PCOS or non-PCOS populations. [27] [28] [29] IGT is likely more related to pancreatic β-cell failure as opposed to IR, and this can be harder to assess in the fasting state. 30 
| Surrogate insulin resistance measures
A total of 12 surrogate IR measures [fasting HOMA-IR, 31 Matsuda index, 11 Stumvoll index, 12 QUICKI, 10 TG:glucose index (TyG), 35 TG:
HDL ratio, 36 e-IS, 22 FGIR, 16 TG, insulin, adiponectin, and HDL, as well For comparison with IGT, in addition to the above measures, we also included HbA1c and HOMA-β, which is meant to represent pan-
12,31
| Statistics
The distributions of all variables were examined and results presented 
| RESULTS
Forty-eight female adolescents were enrolled, 28 with PCOS and 20 controls. Descriptive statistics of these two groups are shown in Table 1 . There was no significant difference in age (P = 0.34), BMIpercentile (P = 0.497) or Z-score (P = 0.291) for sex and age or waist circumference (P = 0.16) between groups. The majority of the cohort was overweight or obese. As expected per study design, the PCOS group had higher FAI (P = 0.003), total testosterone concentration (P = 0.016) and AMH (P = 0.005). Girls in the PCOS group had fewer menses per year (P < 0.001). Table 2 shows raw data and surrogate IR measures stratified by group. Fasting measures were within normal ranges and similar between groups including: HbA1c, adiponectin, fasting glucose from the clamp and OGTT days, and fasting insulin from the clamp and OGTT days. The mean 2-hour OGTT glucose was higher in PCOS, but within "normal" glucose tolerance (P = 0.005). In addition, 2-hour OGTT insulin was significantly higher in PCOS (P = 0.025). The GIR in mg/kgFFM/min was significantly lower in PCOS (P = 0.01), indicating decreased insulin sensitivity.
Twelve IR surrogate indices were calculated for both groups and compared with GIR (data not shown). Within the PCOS group, HOMA-IR (r = −0.78, P < 0.001), e-IS (r = 0.69, P < 0.001), and waist circumference (r = −0.71, P < 0.001) tightly correlated with GIR and Matsuda did so as well, although less strongly (r = 0.55, P = 0.003) (Figure 1 ). Within the entire cohort HOMA-IR (r = −0.70, P < 0.001) and e-IS (r = 0.53, P < 0.001) correlated significantly with GIR.
Associations between GIR and the three most related calculated surrogate measures (HOMA-IR, Matsuda Index, and e-IS) were examined after adjustment for potential confounders in the PCOS group.
Within the PCOS group, HOMA-IR showed a non-significant association with GIR (β = −0.823, P = 0.081) after adjusting for potential confounders including SHBG, FAI, family history of PCOS, and BMI-Z.
The association between e-IS and GIR also did not reach statistical significance (β = 0.873, P = 0.128) nor did Matsuda index (β = 0.127, P = 0.578) after adjustment, indicating that none of the measures was independently associated with GIR. For the entire cohort, after adjustment, HOMA-IR (β = −1.00, P = 0.018) and e-IS (β = 1.229, P = 0.022) were still significantly associated with GIR.
The ROC curve analyses showed that e-IS was the best predictor for IR in both groups, with IR defined as GIR below the median for group (13.5 mg/kgFFM/min in the PCOS cohort). For the HOMA-IR, the area under the ROC curve in the PCOS and control group was 0.88 and 0.76, respectively. e-IS had the largest area under the ROC Figure 2A ). For Matsuda index, the area under the ROC curve was 0.74 and 0.73, respectively. The PCOS cohort only ROC curves in Figure 2A were used to identify optimal cut-off points of e-IS index for prediction of GIR above or below the median. In the PCOS group, a cutoff of less than 6.3 provided the best sensitivity (100%) and specificity (74%) for prediction of GIR below the median. Table 3 shows a sub-analysis of the PCOS group, divided by IGT HOMA-β was also a strong predictor of IGT status (AUC 0.737, P = 0.046).
FIGURE 1
In the polycystic ovarian syndrome cohort only, the relationships between measures of glucose infusion rate from a clamp and surrogate measures of insulin sensitivity including A, homeostatic model assessment (HOMA), B, estimate of insulin sensitivity (e-IS), and C, Matsuda score FIGURE 2 A, In the polycystic ovarian syndrome (PCOS) cohort only, the receiver operating characteristic (ROC) curves for homeostatic model assessment (HOMA), estimate of insulin sensitivity (e-IS) an Matsuda are shown as they predict glucose infusion rate below the mean for girls with PCOS, B, in the PCOS cohort only, ROC curves for fasting measures of insulin resistance as they predict impaired glucose tolerance status for girls with PCOS
| DISCUSSION
We identified the strongest of the available surrogate measures of peripheral IR and IGT in adolescents with PCOS. We found that an e-IS score of less than 6.3, an index derived from waist circumference, fasting TG concentrations and HbA1c, was the best predictor for detecting severe IR in PCOS girls with ROC analysis. The fasting insulin was related to 2 hour glucose concentrations, and had the best sensitivity and specificity to predict IGT status; however, the translatability of our absolute cutoff value to other sites is challenging, because of non-standardization of the insulin assay. Thus, whereas we identified a good, simple to use surrogate measure to identify IR in adolescents with PCOS, the measure for IGT in these girls has some caveats precluding its universal use.
It is not surprising that the e-IS gave the best prediction for low GIR in our patient cohort. e-IS is a formula that was designed specifically for estimating insulin sensitivity in adolescents with and without diabetes across the entire glycemic spectrum. 22 The other measures were developed in adults, who do not have the confounding effects of puberty-induced IR in addition to obesity, PCOS and/or diabetes.
Our results are the first application of this formula and showed that this formula is applicable as well in non-diabetic but IR cohorts (PCOS and obese adolescents). Although e-IS had the same sensitivity and specificity for estimating IR in the PCOS group as HOMA-IR, this formula with its easy-to-obtain parameters has an advantage over cator of IR in their study of 458 PCOS Korean women. 19 Waist circumference has been shown in previous studies to be correlated in IR in non-diabetic women. 37 The third parameter, HbA1c, can reflect early changes in glycemia, due to a combination of IR and β-cell insulin secretion. 38 Finally, as seen in Table 3 , measures of glucose and insulin can change acutely with changes in diet and thus HOMA score can vary from day to day, whereas measures of TG and HbA1c are more stable. However, e-IS did not distinguish IR differences between PCOS and non-PCOS groups which may be due to the referral bias of the obese girls in the control group, several of who were referred for evaluation of hypertriglyceridemia (30%) and thus have a higher TG than typically seen. In a research setting where diet, activity and insulin assays are controlled, HOMA-IR may provide better discriminatory
power. e-IS raises the new possibility of detecting severe IR in PCOS adolescents in a cost-efficient, accurate, and clinically feasible setting from just a fasted blood sample.
Triglyceride-based models of IR have a benefit of less assay vari- Insulin-based models have been shown in multiple populations to predict GIR. HOMA-IR is the most widely used and generally accepted way of estimating IR in all types of patient populations. 15, 31 Nonetheless, this index has a large CV, and is not ideally suited for individual clinical care calculations. 31 We did find that HOMA-IR did have a stronger simple correlation with GIR and had a significant difference between groups, yet the ROC analysis for predicting disease was not as strong. As an alternative, the fasting glucose to insulin ratio has been proposed to be a simple and useful surrogate measure for IR in populations of prepubertal children and adult PCOS patients. Silfen et al. studied 25 prepubertal girls with premature adrenarche (PA) and found that FGIR highly correlated with OGTT measures of IR. 39 In a similar study FGIR was shown to be closely correlated to the frequently sampled intravenous glucose tolerance test (FSIVGTT) in 33 prepubertal girls with PA. 40 Legro et al. also validated the use of FGIR in measuring IR of adult PCOS patients in their study of 40 PCOS non-Hispanic white women. 16 Our results show that FGIR did correlate with GIR in the PCOS group (data not shown, r = 0.49, P = 0.008) and in the entire cohort (data not shown, r = 0.37, P = 0.010). However, GIR did not correlate as strongly as some of our other measures and the use of FGIR requires insulin assay with the limitations discussed above.
It has been more challenging to find good surrogate markers for predicting those with IGT on an OGTT, regardless of PCOS status. [27] [28] [29] Part of the challenge likely relates to the poor reproducibility of an OGTT in any one individual, especially in youth, as well as daily variability in fasting insulin. 41, 42 This was again demonstrated in our data set, with variability in glucose and insulin measurements from clamp and OGTT days, likely secondary to difference in preparation for study days. The OGTT was done "free living" whereas the clamp was preceded by 72 hours of no activity and a controlled diet. Unfortunately, the only markers that were related to IGT were the fasting insulin from the OGTT days and 2-hour insulin concentrations, as well as surrogate markers that include fasting insulin in their calculations.
These associations have been reported in adult women with PCOS, so this finding is consistent across the age span, and not unique to adolescents. [23] [24] [25] [26] IGT reflects the ultimate combination of both IR, but more importantly, relative pancreatic β-cell insufficiency. 41, 42 Similar to results found in adults with pre-diabetes, and in youth with a spectrum of glycemia, we also found that HOMA-β predicted IGT.
Notably, there was no relationship with HbA1c and IGT status in our patients, likely due to the fact that HbA1c relates more to overall average glucose, rather than a response to 75 g of glucose. 43 Thus, similar to adults with and without PCOS, fasting insulin is a moderately accurate marker for IGT status.
Our study has several strengths and weaknesses. As opposed to nearly all studies conducted in youth with PCOS to-date, we compared surrogate indices with peripheral IR as measured by GIR from the gold-standard clamp rather than another 2-hour OGTT derived index. This allowed better evaluation of the accuracy of these indices.
We also have a cohort of participants from a diverse background with various ethnicities and varying family history of PCOS. Moreover, our PCOS and control groups were well-matched and studied in a wellcontrolled setting. However, it is important to note that the sample size is relatively small, which poses challenges as multiple linear regression tests to examine the correlation and ROC between surrogate indices may have been underpowered. We also did not collect data on acanthosis nigricans, another clinical marker of IR. Further, the generalizability of the findings are limited by the sedentary nature of the participants, 80% of the girls were overweight or obese, and as discussed, the obese girls in the "control" group likely have more features of the metabolic syndrome than are typical for the general obese population in the United States.
In conclusion, we found that the e-IS formula, utilizing standardized measurements, is the best predictor of severe IR in PCOS adolescents. The cutoff value of the e-IS formula for predicting GIR above vs below the median value was 6.3 for adolescents with PCOS. Waist circumference, TG, and HbA1c are parameters that can be easily obtained in clinic. Furthermore, e-IS is capable of being adapted into routine clinical use and large epidemiology studies. In terms of IGT, fasting insulin was the best predictor, although our cut-off of 22 IU/ mL is specific to our assay. These markers may be useful tools for early detection of IR and IGT in PCOS adolescents and may allow for more effective prevention of diabetes and CVD in this population.
